Clinical Trial Update: Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) [Phase 2]

View source ↗

Summary

Phase 2 study of Pimicotinib in Japanese participants with Tenosynovial Giant Cell Tumor is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tenosynovial Giant Cell Tumor

Drugs mentioned

• Pimicotinib

Snippet

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Conditions: Tenosynovial Giant Cell Tumor | Phase 2 | Status: RECRUITING